Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

IntroductionSPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety an...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner
Формат: Өгүүллэг
Хэл сонгох:English
Хэвлэсэн: Frontiers Media S.A. 2025-01-01
Цуврал:Frontiers in Oncology
Нөхцлүүд:
castration resistant prostate cancer
PSMA
radioligand therapy
PNT2002
dosimetry
Онлайн хандалт:https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Интернэт

https://www.frontiersin.org/articles/10.3389/fonc.2024.1483953/full

Ижил төстэй зүйлс